Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Dick

Showing results (221-230 of 245) with videos related to

Pageof 25
Sort By:
Progress in Retinal and Eye Research|March 16, 2025
Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapyRyan Purdy, Molly John, Alissa Bray, et al.
Biosensors & Bioelectronics|August 27, 2022
Triazole-derivatized near-infrared cyanine dyes enable local functional fluorescent imaging of ocular inflammationChloe N Thomas, Nada Alfahad, Nicholas Capewell, et al.
Ophthalmology|January 10, 2018
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) InitiativeAndrew D Dick, James T Rosenbaum, Hassan A Al-Dhibi, et al.
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Pediatric Rheumatology Online Journal|May 19, 2025
Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitisAthimalaipet V Ramanan, Andrew D Dick, Thomas Jaki, et al.
The New England Journal of Medicine|September 8, 2016
Adalimumab in Patients with Active Noninfectious UveitisGlenn J Jaffe, Andrew D Dick, Antoine P Brézin, et al.
Health Technology Assessment (Winchester, England)|April 30, 2019
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCTAthimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, et al.
Ebiomedicine|November 6, 2022
Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2Xiao Hu, Yanli Zou, David A Copland, et al.
JAMA Ophthalmology|July 18, 2024
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical TrialSunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, et al.
Ocular Immunology and Inflammation|July 18, 2018
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II TrialsHiroshi Goto, Masahiro Zako, Kenichi Namba, et al.
Pageof 25

Showing results (221-230 of 245) with videos related to

Sort By:
Pageof 25
Progress in Retinal and Eye Research|March 16, 2025
Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapyRyan Purdy, Molly John, Alissa Bray, et al.
Biosensors & Bioelectronics|August 27, 2022
Triazole-derivatized near-infrared cyanine dyes enable local functional fluorescent imaging of ocular inflammationChloe N Thomas, Nada Alfahad, Nicholas Capewell, et al.
Ophthalmology|January 10, 2018
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) InitiativeAndrew D Dick, James T Rosenbaum, Hassan A Al-Dhibi, et al.
Lancet (London, England)|August 21, 2016
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trialQuan Dong Nguyen, Pauline T Merrill, Glenn J Jaffe, et al.
Pediatric Rheumatology Online Journal|May 19, 2025
Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitisAthimalaipet V Ramanan, Andrew D Dick, Thomas Jaki, et al.
The New England Journal of Medicine|September 8, 2016
Adalimumab in Patients with Active Noninfectious UveitisGlenn J Jaffe, Andrew D Dick, Antoine P Brézin, et al.
Health Technology Assessment (Winchester, England)|April 30, 2019
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCTAthimalaipet V Ramanan, Andrew D Dick, Ashley P Jones, et al.
Ebiomedicine|November 6, 2022
Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2Xiao Hu, Yanli Zou, David A Copland, et al.
JAMA Ophthalmology|July 18, 2024
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical TrialSunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, et al.
Ocular Immunology and Inflammation|July 18, 2018
Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II TrialsHiroshi Goto, Masahiro Zako, Kenichi Namba, et al.
Pageof 25